The app-integrated tool automates left ventricular ejection fraction assessment, supporting real-time cardiac evaluation in primary care and emergency settings.
The first human clinical trial of a universal Sarbeco coronavirus vaccine, developed by the University of Cambridge and spin-out DIOSynVax (DVX) Ltd, has shown that the vaccine is safe and has no significant side effects.
The new vaccine aims to produce an immune response that will protect against many pathogens—including some circulating among wild animals that might jump into humans in the future.
GE HealthCare has received FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0, an AI-enabled auto-contouring software designed to assist radiation oncology care teams with treatment planning.
University of Delaware researchers are using artificial intelligence to detect early warning signs hidden in the brain’s electrical rhythms.
GE HealthCare (Nasdaq:GEHC) announced today that it received FDA 510(k) clearance for its MIM Contour ProtégéAI+ 2.0 software.
An international research team led by the A*STAR Genome Institute of Singapore (A*STAR GIS) has developed HERRO, an artificial intelligence (AI) tool that could make it easier and more cost-effective to produce complete, high-quality genome assemblies.
Clarius Mobile Health announced FDA clearance for its Ejection Fraction AI, an intelligent cardiac assessment tool integrated directly into the Clarius ultrasound app.
Researchers used an open-source AI model called Mirai, which was developed by the study’s senior author, UC Berkeley data scientist Adam Yala, Ph.D.
Philips (NYSE:PHG) announced today that it received FDA clearance for its Elevate Plus advanced imaging and AI and automation capabilities.